G2/M inhibitors as pharmacotherapeutic opportunities for glioblastoma: the old, the new, and the future

Glioblastoma (GBM) is one of the deadliest tumors and has a median survival of 3 months if left untreated. Despite advances in rationally targeted pharmacological approaches, the clinical care of GBM remains palliative in intent. Since the majority of altered signaling cascades involved in cancer es...

Full description

Bibliographic Details
Main Authors: Angel Mauricio Castro-Gamero, Julia Alejandra Pezuk, María Sol Brassesco, Luiz Gonzaga Tone
Format: Article
Language:English
Published: China Anti-Cancer Association 2018-12-01
Series:Cancer Biology & Medicine
Subjects:
Online Access:http://www.cancerbiomed.org/index.php/cocr/article/view/1289